z-logo
open-access-imgOpen Access
A combined biomarker and clinical panel for chronic graft versus host disease diagnosis
Author(s) -
Pidala Joseph,
Sigdel Tara K,
Wang Anyou,
Hsieh Sue,
Inamoto Yoshi,
Martin Paul J,
Flowers Mary ED,
Hansen John A,
Lee Stephanie J,
Sarwal Minnie M
Publication year - 2017
Publication title -
the journal of pathology: clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.849
H-Index - 21
ISSN - 2056-4538
DOI - 10.1002/cjp2.58
Subject(s) - graft versus host disease , biomarker , medicine , serostatus , cohort , disease , immunology , oncology , biology , viral load , virus , biochemistry
Whilst many chronic graft versus host disease (cGVHD) biomarkers have been previously reported, few have been verified in an independent cGVHD cohort. We aimed to verify the diagnostic accuracy of previously reported markers of cGVHD in a multi‐centre Chronic GVHD Consortium. A total of 42 RNA and 18 protein candidate biomarkers were assessed amongst 59 cGVHD cases and 33 matched non‐GVHD controls. Total RNA was isolated from PBMC, and RNA markers were quantified using PCR. Serum protein markers were quantified using ELISA. A combined 3 RNA biomarker (IRS2, PLEKHF1 and IL1R2) and 2 clinical variables (recipient CMV serostatus and conditioning regimen intensity) panel accurately (AUC 0.81) segregated cGVHD cases from controls. Other studied RNA and protein markers were not confirmed as accurate cGVHD diagnostic biomarkers. The studied markers failed to segregate higher risk cGVHD (per overall NIH 0‐3 score, and overlap versus classic cGVHD status). These data support the need for multiple independent verification studies for the ultimate clinical application of cGVHD diagnostic biomarkers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here